PD-L1/PD-1 coexpression with CXCR3/CD36 and IL-19 might play an inferior prognostic role in lymphoma, providing a new significant era in lymphoma immunotherapy, especially in patients with extranodal involvement. This evidence concerns the gene CD36 and lymphoma.